| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Santos David A | EVP, Chief Commercial Officer | RIGEL PHARMACEUTICALS, INC., 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO | /s/ Raymond Furey (Attorney-in-Fact) | 17 Sep 2025 | 0001820066 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | RIGL | Employee Stock Option (right to buy) | Award | $0 | +7,394 | $0.000000 | 7,394 | 15 Sep 2025 | Common Stock | 7,394 | $22.49 | Direct | F1, F2 |
| Id | Content |
|---|---|
| F1 | The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On September 15, 2025, it was determined that the performance metric had been met. |
| F2 | The option was fully vested on September 15, 2025, the date the determination was made that the performance metric had been met. |